None listed
Conditions
Interventions
Intervention1: Probiotic containing B.coagulans: 106-108 CFU in the form of
powder to be reconstituted in
milk or water to be consumed in
morning and evening (one
each) for 8 weeks
Control Interventi
Sponsors
Abode Biotec India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1.Healthy male/female of age 18-65 years. 2.FBG ( 3.Normal blood parameters (Hb >= 10 g/dl). 4.Subjects who understand the nature and purpose of the study
Exclusion criteria
Exclusion criteria: 1.Women who are pregnant or Lactating. 2.Subjects who are taking Antibiotic treatment 3.Subjects suffering from Gastrointestinal disease 4.Subjects suffering from Diabetes 5.Subjects suffering from Chronic/iatrogenic immunodeficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect on the systemic and adaptive immune system will be measured by change in ISQ score from baseline to eight weeks of treatment between the intervention group and the placebo groupTimepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Differences in hematological parameters such as CBC in-between the 2 groups over the study period. 2.Differences in Immune parameters such as Kidney Function, Liver Function IgG, IgM, IgA,Lipid Profile in-between the 2 groups over the study periodTimepoint: 8 weeks | — |
Countries
India
Contacts
Public ContactDivya C
Bioagile Therapeutics Pvt. Ltd
Outcome results
None listed